In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
about
The novel fusion proteins, GnRH-p53 and GnRHIII-p53, expression and their anti-tumor effectProtein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugateNGR-peptide-drug conjugates with dual targeting properties.Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumorsImproved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.Drug delivery and release systems for targeted tumor therapy.Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.Peptide-functionalized oxime hydrogels with tunable mechanical properties and gelation behavior.Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.NIR mega-Stokes fluorophores for bioorthogonal labeling and energy transfer systems--an efficient quencher for daunomycin.Investigations on the cell metabolomics basis of multidrug resistance from tumor cells by ultra-performance liquid chromatography-mass spectrometry.Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy.On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids
P2860
Q28534798-E2D09722-5782-410F-8F6B-4112904ED175Q28537657-F81E1F90-BB2A-467B-8D69-2F062B38BF36Q30354486-8685BD2C-5778-4DA1-AF29-707AC4E292D2Q35754246-2A31539C-906F-4E59-9566-F83644C62087Q37034254-089E1514-1059-497F-B08F-220DE98B3A4AQ38363691-9C014FB7-688A-42BB-876B-537CECE3A665Q38882916-060E5AF1-1F2B-4091-974D-7F8B68E33A8CQ42222672-24BD19F7-2C9E-4818-B0CF-529DE60F36E6Q42828662-1D1F5F07-6498-4BB7-9E84-311B3F5BEF18Q45949532-9810FBCE-538C-42E3-B050-8DB9253A1B60Q51662791-B0776E7F-1025-4764-B698-ED7AEA9FF960Q53589895-00DBDF93-6101-4326-8EBE-2D89C8D85FC4Q55054276-8BEECA78-4F12-47AE-8BEC-1058CAD03FB9Q55082165-94C62593-2095-4148-BB6F-1D58CC07A2E8Q55225527-8C75901E-9EF9-41DA-B264-0D205D2080FBQ57821212-14761B96-7837-4E16-9950-FE527C71AB2A
P2860
In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@en
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@nl
type
label
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@en
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@nl
prefLabel
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@en
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@nl
P2093
P2860
P1433
P1476
In vitro degradation and antit ...... ubicin-amino acid metabolites.
@en
P2093
Erika Orbán
Erzsébet Fellinger
Gabriella Csík
Gábor Mezo
Heiko Michael Möller
Marilena Manea
Pascal Schlage
Philipp Ansorge
Zarko Kulić
P2860
P2888
P304
P356
10.1007/S00726-010-0766-1
P577
2010-10-16T00:00:00Z